Camrelizumab

Camrelizumab (SHR-1210) (INN ) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for hepatocellular carcinoma and Hodgkin lymphoma.

This drug is being developed by Jiangsu HengRui Medicine Co., Ltd., camrelizumab is undergoing Phase II/III trials.